New scientific paper published on the mechanism of action of Polyphenon® E, a defined extract from green tea leaves, in preliminary stages of skin cancer
Strausberg, 28 July 2022
DERMAGO GmbH today announced the publication of an article by the research group of PD Dr. J. Eberle from Charité-Universitätsmedizin Berlin, Germany.
The article entitled “Inhibition of Cell Proliferation and Cell Viability by Sinecatechins in Cutaneous SCC Cells Is Related to an Imbalance of ROS and Loss of Mitochondrial Membrane Potential” was released in the peer-reviewed journal Antioxidants1
The complete publication can be found on the internet at the following link
https://www.mdpi.com/2076-3921/11/7/1416
Within the framework of the study, the authors led by PD Dr. Eberle and Prof. Dr. Stockfleth were able to demonstrate that Polyphenon® E induces a concentration-dependent inhibition of cell proliferation as well as a reduction of cell vitality in four different squamous cell carcinoma cell lines (SCL-I, SCL-II, SCC-12 and SCC-13). These modifications correlate with changes in mitochondria as well as with an imbalance of cellular reactive oxygen compounds. The new findings support the previously known comprehensive mechanism of action2 of Polyphenon® E. On the basis of the results, the authors conclude a possible efficacy of Polyphenon® E in the indication actinic keratosis (AK).
Preliminary squamous cell carcinomas such as actinic keratosis (AK) have been among the most common skin diseases treated by dermatologists. Furthermore, a significant increase in actinic keratoses has been observed in the last decade. Apart from etiological factors such as chronic UV exposure, this can be attributed to demographic change with a higher proportion of older people in the population. An estimated 1.7 million people in Germany are currently undergoing dermatological treatment for AK. Actually, the number of patients suffering from AK is much higher and is expected to increase in the next years in line with the population structure. 3
The exclusive manufacturing patents for the active ingredient “Polyphenon® E” (synonyms: “defined extract from green tea leaves” and “sinecatechins”) were taken over by Dermago GmbH from Mitsui Norin Co., Ltd., Japan, in December 2021.
References:
1Zhu, J.; Gillissen, B.; Dang Tran, D.L.; May, S.; Ulrich, C.; Stockfleth, E.; Eberle, J. Inhibition of Cell Proliferation and Cell Viability by Sinecatechins in Cutaneous SCC Cells Is Related to an Imbalance of ROS and Loss of Mitochondrial Membrane Potential. Antioxidants 2022, 11, 1416. https://doi.org/10.3390/antiox11071416
2Apoptotic Gene Expression in Sinecatechins-Treated External Genital and Perianal Warts, Stephen K. Tyring et al, Viral Immunology, Volume 27, Number 10, 2014
Sinecatechins, Effects on HPV-Induced Enzymes Involved in Inflammatory Mediator Generation, Stephen K. Tyring, The Journal of Clinical_Aesthetic Dermatology, January 2012, Volume 5, Number 1
Effect of Sinecatechins on HPV-Activated Cell Growth and Induction of Apoptosis, Stepehn K. Tyring, The Journal of Clinical_Aesthetic Dermatology, February 2012, Volume 5, Number 2
3 S3 guideline actinic keratosis and cutaneous squamous cell carcinoma long version 1.1 – March 2020, AWMF registration number: 032/022OL
Contact data:
DERMAGO Verwaltungs GmbH
Kastanienallee 46
15344 Strausberg, Germany
E-mail: info@dermago-group.com
Phone: 03341-589 90 40